Prescription Drugs Industry Analysis
Stay ahead of the competition with our catalogue of Prescription Drug market reports. Includes data on Europe, UK, USA, Asia and other global markets.
previous
| Medicinal and Botanical Manufacturing Industry in the U.S. and its International Trade (SUU00195) [2012 Q2 Release]The Medicinal and Botanical Manufacturing Industry report contains the most recent data and analysis on the industry's key financial data, cost and pricing, competitive landscape, industry structure. Also updated are... | Apr 2012 | £380 |
| Erythropoietin Market in Japan (INF01659) 2011-2015TechNavio's analysts forecast the Erythropoietin market in Japan to reach US$1.54 billion by 2015. One of the key factors contributing to this market growth is the increase in cases of... | Apr 2012 | £945 |
| Threats to Avastin (ESP00649) Targeting the VEGF Pathway Avastin is set to become the most successful cancer treatment to date and one of the leading drugs with sales likely to exceed US$9 billion by 2015. Since its launch in... | Apr 2012 | £1,295 |
| Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists (LME00145) A Target Pipeline and Stakeholder Analysis 2012This report ""Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists - A Target Pipeline and Stakeholder Analysis 2012"" published in March 2012 provides a compilation of business, commercial, clinical and scientific information about... | Mar 2012 | £1,610 |
| The World Anesthesia Drug Market (General, Local, Adjunctive) (KAL00030) This Kalorama Information report - The World Anesthesia Drug Market - focuses on three primary segments of anesthesia: General Anesthesia Local Anesthesia Adjunctive Therapies in Anesthesia The report covers both currently marketed and late... | Mar 2012 | £2,520 |
| The Market for Prescription Dermatological Drugs, 8th Edition (KAL00188) Antiacne, Antiaging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer, Melasma and Seborrhea TreatmentsThis Kalorama Information report, The Worldwide Market for Prescription Dermatological Drugs represents the eighth time that Kalorama has detailed the various categories of prescription dermatological drugs, describes the global market... | Mar 2012 | £2,520 |
| Neuroendocrine Tumors Drug Pipeline Update 2012 (BSK00080) There are today 50 companies plus partners developing 60 neuroendocrine tumor drugs in 83 developmental projects in cancer. In addition, the accumulated number of ceased drugs over the last years... | Feb 2012 | £825 |
| Lymphoma Drug Pipeline Update 2012 (BSK00047) Lymphoma is a broad term encompassing a variety of cancers of the lymphatic system. There are today 208 companies plus partners developing 293 lymphoma drugs in 406 developmental projects in cancer.... | Feb 2012 | £1,235 |
| Leukemia Drug Pipeline Update 2012 (BSK00050) Leukemia includes a broad variety of histological separate disorders which make the leukemia market segmented. There are today 249 companies plus partners developing 321 leukemia drugs in 474 developmental projects in... | Feb 2012 | £1,235 |
| Melanoma Drug Pipeline Update 2012 (BSK00016) Melanoma comprises just 5% of all skin cancers but it is the most deadly. High unmet needs still persist for this tumor type and despite three decades of extensive R&D,... | Feb 2012 | £1,235 |
| Radiation Therapy in Oncology Drug Pipeline Update 2012 (BSK00078) This drug pipeline update is structured around radiolabeled drugs, radiosensitizers and radioprotective compounds. There are today 318 companies plus partners developing 335 radiation therapy drugs in 663 developmental projects in cancer.... | Feb 2012 | £1,235 |
| Protein Kinase Inhibitors in Oncology Drug Pipeline Update 2012 (BSK00042) Protein kinase inhibitors such as Gleevec, Iressa and Tarceva have allowed the biotechnology industry to deliver on the promise of targeted cancer drugs. However, these three successful drugs are just... | Feb 2012 | £1,235 |
| Antibiotic Resistance 2012 (BPR00025) The Antibiotic Development Pipeline and Strategies to Combat Antibiotic ResistanceThis report gives a comprehensive overview of global antibiotic resistance, the antibiotics pipeline and new strategies to target resistance mechanisms. It identifies 109 antibiotics in the development pipeline, approximately 70%... | Jan 2012 | £1,500 |
| Orphan Drug Markets in Europe (URC00044) Key developments and the strategies of major pharmaceutical companiesThe first marketing authorisations for orphan drugs in Europe took place a decade ago. Since then there have been over 60 designated orphan products. These products now account for annual... | Nov 2011 | £1,495 |
| Orphan Drugs in Europe (JPR00002) Pricing, Reimbursement, Funding and Market Access IssuesThe cost of treating rare disease in an age when austerity measures are hitting total healthcare funding across Europe is a highly controversial, even emotive subject. There is a clear... | Jun 2011 | £1,450 |
| Drug Combinations: New Rules, New Opportunities (FWD00048) Single symptom. Single illness. Single drug. For years, drug therapy has been built on that basic equation. Yet as genomic biology sheds light on the astonishing intricacy of disease pathology, it... | May 2011 | £595 |
| Perspective: FICO Provides Pharmas with New Insight into Medication Nonadherence (IDC10623) This IDC Health Insights Perspective discusses the FICO Medication Adherence Score product used for evaluating patient prescription adherence. | Jan 2011 | £945 |
| Erythropoietin (EPO) (LME00015) Competitor AnalysisThe Competitive Intelligence Report Erythropoietin (EPO) & Erythropoiesis Stimulating Agents (ESA) as of January 2011 in its 5th edition provides information on existing first and second generation epoetin products in... | Jan 2011 | £415 |
| The Pharmaceutical Excipients Market Outlook (RBI00553) Introduction The pharmaceutical excipients market has seen tremendous developments in recent times. Pharmaceutical excipients are increasingly being considered as functional ingredients in contrast to their earlier status as non-functional additives. Consequently,... | Jan 2011 | £2,420 |
| Global Antivirals Market (VIS00068) 2010-2025New report explains how this important anti-infective market will develop In 2009, the global market for antiviral drugs attained total sales of over $28bn. With hundreds of millions of people worldwide... | Feb 2010 | £1,499 |
| Global Drug Eluting Stent Market 2008-2012 (INF01111) Drug Eluting Stents are used for the treatment of heart patients to prevent the need for more-invasive procedures, such as coronary artery bypass surgery. This reduces the need for repeated... | Jan 2010 | £945 |
| Chinese Markets for Anesthetic Drugs (AMI00424) China's demand for Anesthetic Drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new... | Jan 2010 | £2,525 |
| Chinese Markets for Pediatric Drugs (AMI00426) China's demand for Pediatric Drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This... | Jan 2010 | £2,525 |
| Chinese Markets for Tuberculosis Treatment Drugs (AMI00425) China's demand for Tuberculosis Treatment Drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This... | Jan 2010 | £2,525 |
| Distribution and Patient Support for Speciality Medicines in Europe (JPR00007) Speciality medicines (specialty in the US) have become one of the main drivers of pharmaceutical industry growth. High tech, 'high touch' products with premium prices targeted at chronic, complex diseases,... | Sep 2009 | £650 |
